Related Articles
Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy
miR‑342 is associated with estrogen receptor‑α expression and response to tamoxifen in breast cancer
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial
Estradiol suppresses phosphorylation of ERα serine 167 through upregulation of PP2A in breast cancer cells